Astria Therapeutics Q2 EPS $(0.45) Beats $(0.49) Estimate
Portfolio Pulse from Benzinga Newsdesk
Astria Therapeutics reported Q2 losses of $(0.45) per share, beating the analyst consensus estimate of $(0.49) by 8.16%. This represents a 47.67% increase over losses from the same period last year.
August 07, 2023 | 8:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Astria Therapeutics reported better than expected Q2 losses, which could positively impact the stock in the short term.
Astria Therapeutics reported Q2 losses of $(0.45) per share, which is better than the analyst consensus estimate of $(0.49). This beat, which represents a significant improvement over the same period last year, could lead to increased investor confidence and a short-term boost in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100